Both tirzepatide (Mounjaro) and semaglutide (Ozempic) have made headlines in recent months for their benefits in broad patient populations. This new analysis compared the two medications in obese/overweight adults with and without type 2 diabetes.

“This finding shows great potential to enhance the success of chemotherapy while protecting the heart," one researcher said. 

The new list of discounted drugs includes an anticoagulant, a beta-blocker used to treat atrial fibrillation and much more. 

Teva Pharmaceuticals has officially launched generic liraglutide injections in the United States. Novo Nordisk currently sells liraglutide under the brand name Victoza.

Based on positive results from two different trials, Eli Lilly and Company hopes to secure a new FDA approval for tirzepatide in the months ahead.

The new-look diet was linked to significant weight loss and reductions in HbA1C levels. Researchers see it as a potential alternative to immediately putting patients on new medications. 

The recall was put in place due to a leak risk that could make the therapies less effective and potentially lead to an infection. 

The FDA-approved device includes meal detection technology that can deliver insulin when users lose track of time or underestimate how a meal may affect their health.